Silo Pharma (NASDAQ:SILO) Trading Up 1.2% – Here’s What Happened

Silo Pharma, Inc. (NASDAQ:SILO) was up 1.2% during trading on Friday . The stock traded as high as $0.54 and last traded at $0.5150. Approximately 2,112,380 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 9,894,242 shares. The stock had previously closed at $0.5090.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Silo Pharma in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Silo Pharma Stock Performance

The company has a market cap of $8.38 million, a price-to-earnings ratio of -0.95 and a beta of 0.35. The firm has a fifty day moving average price of $0.36 and a 200 day moving average price of $0.42.

Silo Pharma (NASDAQ:SILO) last released its quarterly earnings data on Friday, March 27th. The company reported $0.03 EPS for the quarter. Silo Pharma had a negative return on equity of 83.53% and a negative net margin of 5,870.83%.The company had revenue of $0.02 million during the quarter.

Institutional Investors Weigh In On Silo Pharma

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in Silo Pharma by 134.6% during the 4th quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock valued at $32,000 after purchasing an additional 53,309 shares during the last quarter. Virtu Financial LLC acquired a new stake in Silo Pharma during the 3rd quarter valued at $74,000. AdvisorShares Investments LLC lifted its holdings in Silo Pharma by 98.0% during the 3rd quarter. AdvisorShares Investments LLC now owns 364,878 shares of the company’s stock valued at $252,000 after purchasing an additional 180,642 shares during the last quarter. DRW Securities LLC acquired a new stake in Silo Pharma during the 4th quarter valued at $113,000. Finally, Anson Funds Management LP acquired a new stake in Silo Pharma during the 3rd quarter valued at $657,000. Institutional investors and hedge funds own 5.58% of the company’s stock.

Silo Pharma Company Profile

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.